surmount 5 tirzepatide Presented at #ECO2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body weight and waist circumference. Full trial results Understanding SURMOUNT-5 trial about using

each pen is single-use and contains one weekly dose

- to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition

The PlexusDx Precision Peptide Genetic Test identifies your specific variants across 150+ metabolic insights, revealing whether your body preferentially responds to GIP activation, semaglutide monotherapy, or combination approaches

Although these have not been definitively established as risks specific to retatrutide in early trials, they are recognised class-related concerns

Michelle M

A dummy was placed in the guide cannula to assure its patency